Clinical trial

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

NCT00752427

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-06-01

PhasePHASE3

Study timeline

Study start (unknown)2004-06-01Date precision: month

Registry last updated2011-06-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

Paliperidone ER OROS®DRUG

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00752427 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.